Compare Intel Corp (INTC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs ResMed Inc. — how do they compare? Intel Corp trades at $108.67 (market cap $566.04B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: Intel Corp is far larger — about 17.7× ResMed Inc.'s market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and ResMed Inc. for 51 Days on average.
| INTC | RMD | |
|---|---|---|
Market Cap | $566.04B | $31.89B |
Volume | 118,475,837 | 618,314 |
Sector | Technology | Health |
52-Week High | $140.94 | $277.88 |
52-Week Low | $33.62 | $182.82 |
Typical Hold Time | 116 Days | 51 Days |
Enterprise Value | $586.85B | $31.24B |
Dividend Yield | 2.24% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $113.12, up 0.55% today, with a bullish technical signal and recent earnings beats. The stock has surged over 220% in 2026, driven by AI momentum and foundry growth, though fundamentals show negative net income margins and elevated valuations. Cash flow improved in 2025, but revenue remains below 2022 peaks amid intense competition.
Outlook hinges on foundry turnaround execution; upside exists if Intel captures external customers for advanced nodes, but high debt and margin pressures pose risks. Analyst consensus is cautious with a $111.72 target, slightly below current price, reflecting skepticism on sustainability despite recent gains.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
